Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE

Key Points

• To evaluate the effectiveness of durvalumab combined with carboplatin and paclitaxel as a first-line treatment in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) unable to receive cisplatin-based therapies.
• Multicenter prospective study design
• Target population included frail patients with ECOG-PS of 0-1 and 2
• Intervention with durvalumab and weekly carboplatin/paclitaxel
• Promising results observed in frail patients
• Encouraging response rates in treated cohort
• Supports need for further investigation in phase III clinical trials